Nanotechnology in the diagnosis and management of heart, lung and blood diseases

Expert Review of Molecular Diagnostics

Volumn 7, Issue 2, 2007, Pages 149-160

  Buxton, Denis B ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Cardiovascular; Diagnostics; Hematopoietic; Imaging; Pulmonary; Therapy; Tissue engineering

Indexed keywords

AMPHOTERICIN B; CONTRAST MEDIUM; DNA; DOXORUBICIN; FUMAGILLIN; GADOLINIUM; LOW MOLECULAR WEIGHT HEPARIN; NANOPARTICLE; SMALL INTERFERING RNA; THEOPHYLLINE; TRANSMEMBRANE CONDUCTANCE REGULATOR; TUBERCULOSTATIC AGENT;

AEROSOL; ASTHMA; ATHEROSCLEROSIS; BIOSENSOR; BLOOD DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; COST OF ILLNESS; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; DRUG TARGETING; GENE THERAPY; HEART DISEASE; HUMAN; IMAGING; LUNG DISEASE; LUNG FIBROSIS; LUNG TUBERCULOSIS; MYCOSIS; NANOTECHNOLOGY; NEPHROTOXICITY; NONHUMAN; PLASMID; PROSTHESIS; REVIEW; TISSUE ENGINEERING; TISSUE REPAIR; UNITED STATES;

ANIMALS; HEART DISEASES; HEMATOLOGIC DISEASES; HUMANS; LUNG DISEASES; NANOTECHNOLOGY;

EID: 34047103888     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.7.2.149     Document Type: Review

References (76)

1. Choudhury RP, Fuster V, Fayad ZA. Molecular, cellular and functional imaging of atherothrombosis. Nat. Rev. Drug Discov. 3, 913-925 (2004).
2. Kelly KA, Allport JR, Tsourkas A et al. Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ. Res. 96, 327-336 (2005).
3. Nahrendorf M, Jaffer FA, Kelly KA et al. Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation 114(14), 1504-1511 (2006). •• Novel targeting agent gives improved detection of early-stage atherosclerotic plaque.
4. Aikawa E, Nahrendorf M, Sosnovik D et al. Multimodality molecular imaging identifies proteolytic and osteogenic activities in early aortic valve disease. Circulation 115, 377-386 (2007).
5. Jaffer FA, Nahrendorf M, Sosnovik D et al. Cellular imaging of inflammation in atherosclerosis using magnetofluorescent nanomaterials. Mol. Imaging 5, 85-92 (2006).
6. Trivedi RA, Mallawarachi C, JM, U-King-Im JM et al. Identifying inflamed carotid plaques using in vivo USPIO-enhanced MR imaging to label plaque macrophages. Arterioscler. Thromb. Vasc. Biol. 26, 1601-1606 (2006).
7. 3-integrin-targeted nanoparticles. Circulation 108, 2270-2274 (2003).
8. Flacke S, Fischer S, Scott MJ et al. Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques. Circulation 104, 1280-1285 (2001).
9. Gao X, Yang L, Petros JA et al. In vivo molecular and cellular imaging with quantum dots. Curr. Opin. Biotechnol. 16, 63-72 (2005).
10. Soltesz EG, Kim S, Laurence RG et al. Intraoperative sentinel lymph node mapping of the lung using near-infrared fluorescent quantum dots. Ann. Thorac. Surg. 79, 269-277 (2005).
11. Daldrup-Link HE, Rudelius M, Piontek G et al. Migration of iron oxide-labeled human hematopoietic progenitor cells in a mouse model: in vivo monitoring with 1.5-T MR imaging equipment. Radiology 234, 197-205 (2005).
12. Nitin N, LaConte LE, Zurkiya O, Hu X, Bao G. Functionalization and peptide-based delivery of magnetic nanoparticles as an intracellular MRI contrast agent. J. Biol. Inorg. Chem. 9, 706-712 (2004).
13. Rabin O, Manuel Perez J, Grimm J, Wojtkiewicz G, Weissleder R. An x-ray computed tomography imaging agent based on long-circulating bismuth sulphide nanoparticles. Nat. Mater. 5, 118-122 (2006).
14. Hainfeld JF, Slatkin DN, Focella TM, Smilowitz HM. Gold nanoparticles: a new x-ray contrast agent. Br. J. Radiol. 79, 248-253 (2006).
15. Fatouros PP, Corwin FD, Chen ZJ et al. In vitro and in vivo imaging studies of a new endohedral metallofullerene nanoparticle. Radiology 240(3), 756-764 (2006).
16. Jain KK. Nanotechnology in clinical laboratory diagnostics. Clin. Chim. Acta 358, 37-54 (2005). • Recent review describing some of the nanotechnologies available for medical diagnostics.
17. Bashir R. BioMEMS: state-of-the-art in detection, opportunities and prospects. Adv. Drug Deliv. Rev. 56, 1565-1586 (2004).
18. Cheng MM, Cuda G, Bunimovich YL et al. Nanotechnologies for biomolecular detection and medical diagnostics. Curr. Opin. Chem. Biol. 10, 11-19 (2006).
19. Murphy D, Redmond G. Optical detection and discrimination of cystic fibrosis-related genetic mutations using oligonucleotide-nanoparticle conjugates. Anal. Bioanal. Chem. 381, 1122-1129 (2005).
20. Zhang J, Lang HP, Huber F et al. Rapid and label-free nanomechanical detection of biomarker transcripts in human RNA. Nat. Nanotech. 1, 214-220 (2006).
21. Georganopoulou DG, Chang L, Nam JM et al. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc. Natl Acad. Sci. USA 102, 2273-2276 (2005).
22. Stoeva SI, Lee JS, Smith JE, Rosen ST, Mirkin CA. Multiplexed detection of protein cancer markers with biobarcoded nanoparticle probes. J. Am. Chem. Soc. 128, 8378-9379 (2006). •• Ultrasensitive protein detection that can be multiplexed to detect multiple proteins simultaneously.
23. Kumar A, Aravamudhan S, Gordic M, Bhansali S, Mohapatra SS. Ultrasensitive detection of cortisol with enzyme fragment complementation technology using functionalized nanowire. Biosens. Bioelectron. (2006) (Epub ahead of print).
24. Aravamudhan S, Kumar A, Mohapatra S, Bhansali S. Sensitive estimation of total cholesterol in blood using Au nanowires based micro-fluidic platform. Biosens. Bioelectron. (2007) (Epub ahead of print).
25. Malinski T. Understanding nitric oxide physiology in the heart: a nanomedical approach. Am. J. Cardiol. 96, 13i-24i (2005).
26. Mason RP, Kalinowski L, Jacob RF, Jacoby AM, Malinski T. Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation 112, 3795-3801 (2005).
27. Gradishar WJ, Tjulandin S, Davidson N et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 23, 7794-7803 (2005).
28. Sparreboom A, Baker SD, Verweij J. Paclitaxel repackaged in an albumin-stabilized nanoparticle: handy or just a dandy? J. Clin. Oncol. 23, 7765-7767 (2005).
29. Hoffart V, Lamprecht A, Maincent P et al. Oral bioavailability of a low molecular weight heparin using a polymeric delivery system. J. Control Release 113, 38-42 (2006).
30. Zhang L, Hoffman JA, Ruoslahti E. Molecular profiling of heart endothelial cells. Circulation 112, 1601-1611 (2005). • Example of the use of phage display to find tissue-specific endothelial targets for imaging and drug delivery.
31. Pilch J, Brown DM, Komatsu M et al. Peptides selected for binding to clotted plasma accumulate in tumor stroma and wounds. Proc. Natl Acad. Sci. USA 103(8), 2800-2804 (2006).
32. Hoshino A, Fujioka K, Oku T et al. Quantum dots targeted to the assigned organelle in living cells. Microbiol. Immunol. 48, 985-994 (2004).
33. 3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 26, 2103-2109 (2006).
34. Jeon O, Kang SW, Lim HW, Hyung Chung J, Kim BS. Long-term and zero-order release of basic fibroblast growth factor from heparin-conjugated poly(L-lactide-co-glycolide) nanospheres and fibrin gel. Biomaterials 27, 1598-1607 (2006).
35. Uwatoku T, Shimokawa H, Abe K et al. Application of nanoparticle technology for the prevention of restenosis after balloon injury in rats. Circ. Res. 92, e62-e69 (2003).
36. Banai S, Chorny M, Gertz SD et al. Locally delivered nanoencapsulated tyrphostin (AGL-2043) reduces neointima formation in balloon-injured rat carotid and stented porcine coronary arteries. Biomaterials 26, 451-461 (2005).
37. Bhargava B, Reddy NK, Karthikeyan G et al. A novel paclitaxel-eluting porous carbon-carbon nanoparticle coated, nonpolymeric cobalt-chromium stent: evaluation in a porcine model. Catheter. Cardiovasc. Interv. 67(5), 698-702 (2006). • Novel nanoparticle-coated stent demonstrates promise for reducing inflammatory responses.
38. Richter GM, Stampfl U, Stampfl S et al. A new polymer concept for coating of vascular stents using PTFEP (poly(bis(trifluoroethoxy)phosphazene) to reduce thrombogenicity and late in-stent stenosis. Invest. Radiol. 40, 210-218 (2005).
39. Oberdorster G, Oberdorster E, Oberdorster J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ. Health Perspect. 113, 823-839 (2005).
40. Heyder J, Gebhart J, Rudolf G, Schiller C, Stahlhofen W. Deposition of particles in the human respiratory tract in the size range 0.005-15 μm. J. Aerosol Sci. 17, 811-825 (1986).
41. Tsapis N, Bennett D, Jackson B, Weitz DA, Edwards DA. Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc. Natl Acad. Sci. USA 99, 12001-12005 (2002).
42. Grenha A, Seijo B, Remunan-Lopez C. Microencapsulated chitosan nanoparticles for lung protein delivery. Eur. J. Pharm. Sci. 25, 427-437 (2005).
43. Pandey R, Khuller GK. Antitubercular inhaled therapy: opportunities, progress and challenges. J. Antimicrob. Chemother. 55, 430-435 (2005).
44. Pandey R, Sharma A, Zahoor A et al. Poly (DL-lactide-co- glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J. Antimicrob. Chemother. 52, 981-986 (2003).
45. Lee DW, Shirley SA, Lockey RF, Mohapatra SS. Thiolated chitosan nanoparticles enhance anti-inflammatory effects of intranasally delivered theophylline. Respir. Res. 7, 112 (2006).
46. Zhang W, Yang H, Kong X et al. Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nat. Med. 11, 56-62 (2005).
47. Konstan MW, Davis PB, Wagener JS et al. Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution. Hum. Gene Ther. 15, 1255-1269 (2004). •• Clinical trial demonstrating the potential of nanoparticles as a gene delivery tool in patients.
48. Fink TL, Klepcyk PJ, Oette SM et al. Plasmid size up to 20 kbp does not limit effective in vivo lung gene transfer using compacted DNA nanoparticles. Gene Ther. 13, 1048-1051 (2006).
49. Hoeben BJ, Burgess DS, McConville JT et al. In vivo efficacy of aerosolized nanostructured itraconazole formulations for prevention of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 50, 1552-1554 (2006).
50. Kleemann E, Neu M, Jekel N et al. Nano-carriers for DNA delivery to the lung based upon a TAT-derived peptide covalently coupled to PEG-PEI. J. Control Release 109, 299-316 (2005).
51. Dinauer N, Balthasar S, Weber C et al. Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes. Biomaterials 26, 5898-5906 (2005).
52. Kwon YJ, James E, Shastri N, Frechet JM. In vivo targeting of dendritic cells for activation of cellular immunity using vaccine carriers based on pH-responsive microparticles. Proc. Natl Acad. Sci. USA 102, 18264-18268 (2005).
53. Kwon YJ, Standley SM, Goh SL, Frechet JM. Enhanced antigen presentation and immunostimulation of dendritic cells using acid-degradable cationic nanoparticles. J. Control Release 105(3), 199-212 (2005).
54. Wang X, Uto T, Sato K et al. Potent activation of antigen-specific T cells by antigen-loaded nanospheres. Immunol. Lett. 98, 123-130 (2005).
55. Ellis-Behnke RG, Liang Y-X, Tay DKC et al. Nano hemostat solution: immediate hemostasis at the nanoscale. Nanomed. Nanotech. Biol. Med. 2 (2006). •• Use of self-assembling peptides forming nanofibers to give ultra-rapid hemostasis.
56. Yokoi H, Kinoshita T, Zhang S. Dynamic reassembly of peptide RADA16 nanofiber scaffold. Proc. Natl Acad. Sci. USA 102, 8414-8419 (2005).
57. Norman JJ, Desai TA. Methods for fabrication of nanoscale topography for tissue engineering scaffolds. Ann. Biomed. Eng. 34, 89-101 (2006).
58. Zong X, Bien H, Chung CY et al. Electrospun fine-textured scaffolds for heart tissue constructs. Biomaterials 26, 5330-5338 (2005).
59. Ishii O, Shin M, Sueda T, Vacanti JP. In vitro tissue engineering of a cardiac graft using a degradable scaffold with an extracellular matrix-like topography. J. Thorac. Cardiovasc. Surg. 130, 1358-1363 (2005). • Use of nanofibrous scaffolds to engineer myocardium in vitro.
60. Davis ME, Motion JP, Narmoneva DA et al. Injectable self-assembling peptide nanofibers create intramyocardial microenvironments for endothelial cells. Circulation 111, 442-450 (2005).
61. Narmoneva DA, Oni O, Sieminski AL et al. Self-assembling short oligopeptides and the promotion of angiogenesis. Biomaterials 26, 4837-4846 (2005).
62. Hsieh PC, Davis ME, Gannon J, MacGillivray C, Lee RT. Controlled delivery of PDGF-BB for myocardial protection using injectable self-assembling peptide nanofibers. J. Clin. Invest. 116, 237-248 (2006).
63. Hsieh PC, MacGillivray C, Gannon J, Cruz FU, Lee RT. Local controlled intramyocardial delivery of platelet-derived growth factor improves postinfarction ventricular function without pulmonary toxicity. Circulation 114, 637-644 (2006). •• Self-assembling peptides provide a nanostructured environment to preserve myocardium.
64. Davis ME, Hsieh PC, Takahashi T et al. Local myocardial insulin-like growth factor 1 (IGF-1) delivery with biotinylated peptide nanofibers improves cell therapy for myocardial infarction. Proc. Natl Acad. Sci. USA 103, 8155-8160 (2006).
65. Mondrinos MJ, Koutzaki S, Jiwanmall E et al. Engineering three-dimensional pulmonary tissue constructs. Tissue Eng. 12, 717-728 (2006).
66. Nel A, Xia T, Madler L, Li N. Toxic potential of materials at the nanolevel. Science 311, 622-627 (2006). • Recent review highlighting the potential toxicities on nanoscale materials and the underlying mechanisms.
67. Radomski A, Jurasz P, Alonso-Escolano D et al. Nanoparticle-induced platelet aggregation and vascular thrombosis. Br. J. Pharmacol. 146, 882-893 (2005).
68. Shvedova AA, Castranova V, Kisin ER et al. Exposure to carbon nanotube material: assessment of nanotube cytotoxicity using human keratinocyte cells. J. Toxicol. Environ. Health A 66, 1909-1926 (2003).
69. Oberdorster G, Maynard A, Donaldson K et al. Principles for characterizing the potential human health effects from exposure to nanomaterials: elements of a screening strategy. Part. Fibre Toxicol. 2, 8 (2005).
70. Lee JH, Huh YM, Jun YW et al. Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nat. Med. 13, 95-99 (2007).
71. Kling J. Moving diagnostics from the bench to the bedside. Nat. Biotechnol. 24, 891-893 (2006).
72. Labhasetwar V. Nanotechnology for drug and gene therapy: the importance of understanding molecular mechanisms of delivery. Curr. Opin. Biotechnol. 16, 674-680 (2005).
73. US FDA nanotechnology site www.fda.gov/nanotechnology
74. Nanotechnology at National Institute for Occupational Safety and Health www.cdc.gov/niosh/topics/nanotech/default.html
75. National Toxicology Program http://ntp.niehs.nih.gov/index.cfm?objectid= 7E6B19D0-BDB5-82F8-FAE73011304F542A
76. National Cancer Institute Alliance for Nanotechnology in cancer http://nano.cancer.gov/about_alliance/nanotech_characterization_lab.asp Expert Rev. Mol. Diagn. 7(2), 161-175 (2007)